the new hire, page-4

I'm with you Skint.

The most important aspect of PRANA's future that (non short term trading) shareholders should be concerned (and excited) about are the results of the the two current trials. They are what will potentially make or break the company. All the current vibes are exuding a positive atmosphere at the moment.

Pete Smith will be PART OF A TEAM (not the final arbiter) of PBT's path to commercialisation should it demonstrate the scientific results to warrant such.

I don't think HC sentiment would have caused the apparent US sell down on his appointment though. More likely US investors aware of, and reacting to, his involvement in Alchemia's failed IPO bid. There is no connection between what happened there and his proposed role with Prana and this negative sentiment will be inconsequential as the October results approach.

So, in the meantime I am not about to panic over his appointment.

All my opinion only.